EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 Infection in Children with Cancer: Experience from a Tertiary Care Center in North India

Pritam Singha Roy, Manjinder Singh Randhawa, Karthi Nallasamy, Mini P. Singh, Srinivasan Peyam, Prashant Chhabra, Gnanamani Senguttuvan, Safal Muhammed, Mukesh Dhankar, Richa Jain, Deepak Bansal, Amita Trehan

Indian Journal of Medical and Paediatric Oncology · 01.08.2023 · 44 (04) · 428-435

DOI: 10.1055/s-0043-1764366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.08.2023. Verfasst von Pritam Singha Roy und 11 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Children with cancer are immunocompromised due to the disease per se or anticancer therapy. Children are believed to be at a lower risk of severe coronavirus disease 2019 (COVID-19) disease.

Objective

This study analyzed the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children with cancer. Materials and Methods A retrospective analysis was performed on patients (≤ 14 years) with cancer attending the pediatric oncology services of our institute who tested positive for the SARS-CoV-2 infection and those who had COVID-19 disease between August 2020 and May 2021. Real-time reverse transcriptase-polymerase chain reaction performed on the nasopharyngeal swab identified the SARS-CoV-2 infection. The primary endpoints were clinical recovery, interruption of cancer treatment, and associated morbidity and mortality.

Results

Sixty-six (5.7%) of 1,146 tests were positive for the SARS-CoV-2 infection. Fifty-two (79%) and 14 (21%) patients had hematolymphoid and solid malignancies. Thirty-two (48.5%) patients were asymptomatic. A mild-moderate, severe, or critical disease was observed in 75% (18/24), 12.5% (3/24), and 12.5% (3/24) of the symptomatic patients. The “all-cause” mortality was 7.6% (5/66), with only one (1.5%) death attributable to COVID-19. Two (3%) patients required ventilation. Two (3%) patients had a delay in cancer diagnosis secondary to COVID-19 infection. Thirty-eight (57.6%) had a disruption in anticancer treatment.

Conclusion

Children with cancer do not appear to be at an increased risk of severe illness due to SARS-CoV-2 infection. Our findings substantiate continuing the delivery of nonintensive anticancer treatment unless sick. However, SARS-CoV-2 infection interrupted anticancer therapy in a considerable proportion of children.

Zitieren

APA

Roy, P. S., Randhawa, M. S., Nallasamy, K., Singh, M. P., Peyam, S., Chhabra, P., Senguttuvan, G., Muhammed, S., Dhankar, M., Jain, R., Bansal, D., & Trehan, A. (2023). SARS-CoV-2 Infection in Children with Cancer: Experience from a Tertiary Care Center in North India. Indian Journal of Medical and Paediatric Oncology, 44(04), 428-435. https://doi.org/10.1055/s-0043-1764366

Vancouver

Roy PS, Randhawa MS, Nallasamy K, Singh MP, Peyam S, Chhabra P, et al. SARS-CoV-2 Infection in Children with Cancer: Experience from a Tertiary Care Center in North India. Indian Journal of Medical and Paediatric Oncology. 2023;44(04):428-435. doi:10.1055/s-0043-1764366

BibTeX
@article{Roy2023,
  author = {Roy, Pritam Singha and Randhawa, Manjinder Singh and Nallasamy, Karthi and Singh, Mini P. and Peyam, Srinivasan and Chhabra, Prashant and Senguttuvan, Gnanamani and Muhammed, Safal and Dhankar, Mukesh and Jain, Richa and Bansal, Deepak and Trehan, Amita},
  title = {SARS-CoV-2 Infection in Children with Cancer: Experience from a Tertiary Care Center in North India},
  journal = {Indian Journal of Medical and Paediatric Oncology},
  year = {2023},
  volume = {44},
  number = {04},
  pages = {428--435},
  doi = {10.1055/s-0043-1764366}
}
Kostenlos starten →